Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings

Download
2014-07-01
Gungor, Bilgi
Yagci, Fuat Cem
GÜRSEL, İHSAN
Gürsel, Mayda
Type I interferon inducers may potentially be engineered to function as antiviral and anticancer agents, or alternatively, vaccine adjuvants, all of which may have clinical applications. We recently described a simple strategy to convert a Toll-like receptor 9 (TLR9) agonist devoid of interferon alpha (IFN alpha) stimulating activity into a robust Type I interferon inducer with potent vaccine adjuvant activity.
Citation Formats
B. Gungor, F. C. Yagci, İ. GÜRSEL, and M. Gürsel, “Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings,” ONCOIMMUNOLOGY, vol. 3, no. 7, pp. 0–0, 2014, Accessed: 00, 2020. [Online]. Available: https://hdl.handle.net/11511/42937.